These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 28685212)
1. Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers. Viala M; Alexandre M; Thezenas S; Lamy PJ; Maran-Gonzalez A; Gutowski M; Colombo PE; Romieu G; Jacot W; Guiu S Breast Cancer Res Treat; 2017 Oct; 165(3):611-621. PubMed ID: 28685212 [TBL] [Abstract][Full Text] [Related]
2. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M; J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112 [TBL] [Abstract][Full Text] [Related]
3. Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer. Kolben T; Augustin D; Armbrust R; Kolben TM; Degenhardt T; Burgmann M; Goess C; Ditsch N; Kates R; Harbeck N; Wuerstlein R Breast Cancer Res Treat; 2016 Jan; 155(1):109-15. PubMed ID: 26643086 [TBL] [Abstract][Full Text] [Related]
4. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061 [TBL] [Abstract][Full Text] [Related]
5. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C; Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655 [TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer. Saadoun H; Lamy PJ; Thezenas S; Pouderoux S; Bibeau F; Montels F; Romieu G; Colombo PE; Gutowski M; Jacot W Future Oncol; 2014 Feb; 10(2):195-209. PubMed ID: 24490606 [TBL] [Abstract][Full Text] [Related]
8. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy. Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864 [TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. Harbeck N; Kates RE; Schmitt M J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823 [TBL] [Abstract][Full Text] [Related]
10. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up. Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573 [TBL] [Abstract][Full Text] [Related]
11. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417 [TBL] [Abstract][Full Text] [Related]
12. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647 [TBL] [Abstract][Full Text] [Related]
13. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer. Pusina S Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164 [TBL] [Abstract][Full Text] [Related]
14. Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine: Results of a prospective multi-center study at certified breast centers. Jacobs VR; Augustin D; Wischnik A; Kiechle M; Hoess C; Steinkohl O; Rack B; Kapitza T; Krase P Breast; 2016 Oct; 29():208-12. PubMed ID: 27344290 [TBL] [Abstract][Full Text] [Related]
15. Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome. Witzel ID; Milde-Langosch K; Wirtz RM; Roth C; Ihnen M; Mahner S; Zu Eulenburg C; Jänicke F; Müller V J Cancer Res Clin Oncol; 2010 Nov; 136(11):1709-18. PubMed ID: 20204407 [TBL] [Abstract][Full Text] [Related]
16. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Duffy MJ; McGowan PM; Harbeck N; Thomssen C; Schmitt M Breast Cancer Res; 2014 Aug; 16(4):428. PubMed ID: 25677449 [TBL] [Abstract][Full Text] [Related]
17. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1. Ettl J; Klein E; Hapfelmeier A; Grosse Lackmann K; Paepke S; Petry C; Specht K; Wolff L; Höfler H; Kiechle M PLoS One; 2017; 12(9):e0183917. PubMed ID: 28877230 [TBL] [Abstract][Full Text] [Related]
18. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466 [TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Harbeck N; Kates RE; Schmitt M; Gauger K; Kiechle M; Janicke F; Thomassen C; Look MP; Foekens JA Clin Breast Cancer; 2004 Dec; 5(5):348-52. PubMed ID: 15585071 [TBL] [Abstract][Full Text] [Related]
20. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. Look MP; van Putten WL; Duffy MJ; Harbeck N; Christensen IJ; Thomssen C; Kates R; Spyratos F; Fernö M; Eppenberger-Castori S; Sweep CG; Ulm K; Peyrat JP; Martin PM; Magdelenat H; Brünner N; Duggan C; Lisboa BW; Bendahl PO; Quillien V; Daver A; Ricolleau G; Meijer-van Gelder ME; Manders P; Fiets WE; Blankenstein MA; Broët P; Romain S; Daxenbichler G; Windbichler G; Cufer T; Borstnar S; Kueng W; Beex LV; Klijn JG; O'Higgins N; Eppenberger U; Jänicke F; Schmitt M; Foekens JA J Natl Cancer Inst; 2002 Jan; 94(2):116-28. PubMed ID: 11792750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]